陇神戎发：产品“血液透析浓缩液”取得注册证

Group 1 - The core point of the article is that Longshen Rongfa has received a medical device registration certificate for its "blood dialysis concentrate" from the National Medical Products Administration of China, effective November 28, 2025 [1] - Longshen Rongfa's revenue composition for the first half of 2025 shows that pharmaceutical sales account for 86.53%, medical device sales for 6.69%, logistics distribution for 4.48%, property leasing for 0.76%, and consulting services for 0.7% [1] - As of the report date, Longshen Rongfa has a market capitalization of 3.1 billion yuan [1]